KR950702561A - 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs) - Google Patents
퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs) Download PDFInfo
- Publication number
- KR950702561A KR950702561A KR1019950700158A KR19950700158A KR950702561A KR 950702561 A KR950702561 A KR 950702561A KR 1019950700158 A KR1019950700158 A KR 1019950700158A KR 19950700158 A KR19950700158 A KR 19950700158A KR 950702561 A KR950702561 A KR 950702561A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- hydrogen
- diazabicyclo
- methyl
- naphthyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
하기 일반식 (I)의 3-카복스알데하이드 퀴놀린 및 나프티리딘은 항균활성을 갖는다 :
상기 식에서, A, Y, R1및 R2는 본원에 정의된 바와 같이, 이러한 화합물은 주사에 의해서 투여하기에 특히 적합하다. 이러한 화합물의 특정한 예는 1-사이클로프로필-6-플루오로-7-[(1S,4S)-5-메틸-2,5-디아자비사이클로[2.2.1]헵트-2-일]-4-옥소-1,4-디하이드로퀴놀린-3-카복스알데하이드이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 하기 일반식의 화합물, 및 하기 일반식에서 R2가 수소가 아닌 경우 그의 약학적으로 허용가능한 산 부가염 :상기 식에서, A는 CH, CF 또는 N이고; Y는 에틸, 사이클로프로필, 4-플루오로페닐 또는 2,4-디플루오로페닐이거나; 또는 A 및 Y는 함께이고; R1은 수소 또는 메틸이고; R2는 수소, 5-메틸-2,5-디아자비사이클로[2.2.1]헵트-2-일, 8-메틸-3,8-디아자비사이클로[3.2.1]옥트-3-일, 1,4-디아자비사이클로[3.2.2]논-4-일이고; 단, R2가 수소일 경우, A 및 Y는 함께이다.
- 제1항에 있어서, 상기 화합물이 빈플록사신 또는 플루메퀸의 3-카복스알데하이드 유도체인 화합물.
- 제1항에 있어서, 상기 화합물이 다노플록사신의 3-카복스알데하이드 유도체인 화합물.
- 제1항 내지 제3항중 어느 한 항에 따른 화합물 및 약학적으로 허용가능한 담체를 포함하는 항균성 조성물.
- 제4항에 있어서, 상기 담체가 주사액인 조성물.
- 제1항 내지 제3항중 어느 한 항에 따른 화합물의 항균 효과량을 세균에 감염된 숙주에게 투여함을 포함하는, 세균에 감염된 숙주의 치료방법.
- 제6항에 있어서, 주사에 의해서 투여하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/914188 | 1992-07-15 | ||
| US07/914,188 US5235054A (en) | 1992-07-15 | 1992-07-15 | 3-carboxaldehyde substituted quinolines and naphthyridines |
| PCT/US1993/003624 WO1994002480A1 (en) | 1992-07-15 | 1993-04-23 | Quinoline and naphthyridine prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950702561A true KR950702561A (ko) | 1995-07-29 |
Family
ID=25434020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950700158A KR950702561A (ko) | 1992-07-15 | 1993-04-23 | 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs) |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5235054A (ko) |
| EP (1) | EP0650488A1 (ko) |
| JP (1) | JPH07504684A (ko) |
| KR (1) | KR950702561A (ko) |
| CN (1) | CN1083053A (ko) |
| AU (1) | AU669958B2 (ko) |
| BR (1) | BR9306733A (ko) |
| CA (1) | CA2140135A1 (ko) |
| CZ (1) | CZ280603B6 (ko) |
| FI (1) | FI933203A (ko) |
| HU (1) | HUT68745A (ko) |
| IL (1) | IL106264A0 (ko) |
| MX (1) | MX9304266A (ko) |
| NO (1) | NO950142L (ko) |
| NZ (1) | NZ252847A (ko) |
| PL (1) | PL307135A1 (ko) |
| RU (1) | RU2097379C1 (ko) |
| SK (1) | SK4695A3 (ko) |
| WO (1) | WO1994002480A1 (ko) |
| ZA (1) | ZA935076B (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8448491A (en) * | 1990-09-07 | 1992-03-30 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| IL124454A (en) * | 1995-12-21 | 2003-10-31 | Pfizer | Injectable danofloxacin formulations |
| JO3077B1 (ar) * | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينولين مضادة للبكتيريا |
| MX2011012134A (es) | 2009-05-15 | 2012-02-08 | Redx Pharma Ltd | Derivados de farmaco de oxido-reduccion. |
| WO2020184578A1 (ja) * | 2019-03-11 | 2020-09-17 | 小胞体ストレス研究所株式会社 | 新規なｅＩＦ２αのリン酸化促進剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2509728A1 (fr) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| IN166416B (ko) * | 1985-09-18 | 1990-05-05 | Pfizer | |
| JP2777661B2 (ja) * | 1988-10-20 | 1998-07-23 | 大塚製薬株式会社 | ベンゾヘテロ環化合物 |
-
1992
- 1992-07-15 US US07/914,188 patent/US5235054A/en not_active Expired - Lifetime
-
1993
- 1993-04-23 AU AU55746/94A patent/AU669958B2/en not_active Ceased
- 1993-04-23 JP JP6503987A patent/JPH07504684A/ja active Pending
- 1993-04-23 CZ CZ95101A patent/CZ280603B6/cs unknown
- 1993-04-23 NZ NZ252847A patent/NZ252847A/en unknown
- 1993-04-23 KR KR1019950700158A patent/KR950702561A/ko not_active Application Discontinuation
- 1993-04-23 WO PCT/US1993/003624 patent/WO1994002480A1/en not_active Application Discontinuation
- 1993-04-23 RU RU9595105159A patent/RU2097379C1/ru active
- 1993-04-23 BR BR9306733A patent/BR9306733A/pt not_active Application Discontinuation
- 1993-04-23 EP EP93912293A patent/EP0650488A1/en not_active Withdrawn
- 1993-04-23 SK SK46-95A patent/SK4695A3/sk unknown
- 1993-04-23 PL PL93307135A patent/PL307135A1/xx unknown
- 1993-04-23 CA CA002140135A patent/CA2140135A1/en not_active Abandoned
- 1993-07-07 IL IL106264A patent/IL106264A0/xx unknown
- 1993-07-14 ZA ZA935076A patent/ZA935076B/xx unknown
- 1993-07-14 CN CN93108457A patent/CN1083053A/zh active Pending
- 1993-07-14 MX MX9304266A patent/MX9304266A/es not_active Application Discontinuation
- 1993-07-14 HU HU9302018A patent/HUT68745A/hu unknown
- 1993-07-14 FI FI933203A patent/FI933203A/fi unknown
-
1995
- 1995-01-13 NO NO950142A patent/NO950142L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU669958B2 (en) | 1996-06-27 |
| US5235054A (en) | 1993-08-10 |
| HUT68745A (en) | 1995-07-28 |
| NZ252847A (en) | 1996-07-26 |
| IL106264A0 (en) | 1993-11-15 |
| CZ280603B6 (cs) | 1996-03-13 |
| AU5574694A (en) | 1994-02-14 |
| FI933203A0 (fi) | 1993-07-14 |
| NO950142D0 (no) | 1995-01-13 |
| ZA935076B (en) | 1995-01-16 |
| RU95105159A (ru) | 1997-02-10 |
| RU2097379C1 (ru) | 1997-11-27 |
| FI933203A (fi) | 1994-01-16 |
| SK4695A3 (en) | 1995-07-11 |
| CN1083053A (zh) | 1994-03-02 |
| MX9304266A (es) | 1994-01-31 |
| CZ10195A3 (en) | 1995-09-13 |
| WO1994002480A1 (en) | 1994-02-03 |
| NO950142L (no) | 1995-01-13 |
| EP0650488A1 (en) | 1995-05-03 |
| CA2140135A1 (en) | 1994-02-03 |
| PL307135A1 (en) | 1995-05-02 |
| HU9302018D0 (en) | 1993-10-28 |
| JPH07504684A (ja) | 1995-05-25 |
| BR9306733A (pt) | 1999-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041770A1 (es) | Polipeptido ciclico con actividad antimicrobiana y procedimiento de preparacion del mismo | |
| TW376319B (en) | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine | |
| RU98102398A (ru) | Использование ингибиторов cgmp-фосфодиэстеразы для лечения импотенции | |
| KR890001537A (ko) | 5ht-3 길항제의 용도 | |
| FI905718A (fi) | Transdermalt medel. | |
| ATE146186T1 (de) | Trifluormethylketon peptid derivate mit hle- inhibierende aktivität, deren herstellung und pharmazeutischen zusammensetzungen | |
| RU2006118789A (ru) | 2-цианопирролидинкарбоксамидное соединение | |
| EA199901015A1 (ru) | 4"-замещенные производные 9-деоксо-9а-а3а-9а-гомоэритромицина а | |
| ES2095802A1 (es) | Composicion farmaceutica estabilizada y solvente de estabilizacion. | |
| KR900014381A (ko) | 올레핀 1h-이미다조 [4,5-c]퀴놀린-4-아민 | |
| NZ330369A (en) | aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester | |
| KR880005093A (ko) | 5-알킬벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 약제학적 조성물 | |
| WO1992019617A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| DE69030616D1 (de) | Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion | |
| KR950702561A (ko) | 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs) | |
| KR940702726A (ko) | 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법 | |
| RU94045866A (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения | |
| EP0404737A3 (en) | New r(-) 3-quinuclidinol derivatives | |
| RU2008102912A (ru) | Сочетание ингибиторов бетта-лактазмы бициклического 6-алкилиденпенема с бетта-лактанным антибиотиком: антибиотик широкого спектра | |
| DE10299023I1 (de) | Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff | |
| KR890003755A (ko) | 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물 | |
| BE881834A (fr) | Medicaments et preparations pharmaceutiques a activite cytostatique | |
| SI9300150B (sl) | Kristalne oblike endo-2,3-dihidro-N-(8-metil-8-azabicilo/3.2.1./okt-3-il)-2-okso-1H- benzimidazol-1-karboksamid hidroklorid monohidrata in endo-3-etil-2,3-dihidro-N-(8-metil-8-azabiciklo/3.2.1/okt-3-il)-2-okso- 1H-benzimidazol-1-karboksamid hidroklorid monohidrata | |
| ES353413A1 (es) | Procedimiento para la obtencion de composiciones para com- batir la coccidiosis en los pollos. | |
| KR930023338A (ko) | 데포우 제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |